After initial denial, capital raise reveals strong demand for biotech's stock.
NBR staff Fri, 24 Sep 2021
NZX market regulator NZ RegCo is looking further into disclosures made by cancer diagnostics company Pacific Edge ahead of its announcement of a $80 million capital raise yesterday.
Last week Pacific Edge denied it was raising capital after information posted to the ASX as part of its planned
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
